Psychedelic advocates in Oregon are criticizing the FDA’s recent decision to reject MDMA therapy for the treatment of PTSD. The decision has sparked backlash among those who believe in the potential benefits of using psychedelics in therapy.
Despite a growing body of research showing promising results for using MDMA to treat PTSD, the FDA cited concerns about the drug’s safety and efficacy in its recent decision. Advocates argue that this decision will have a detrimental impact on individuals suffering from PTSD who may have found relief through MDMA therapy.
Oregon has been at the forefront of the psychedelic therapy movement, with voters approving Measure 109 in 2020 to legalize the use of psilocybin for therapeutic purposes. Advocates in the state have been pushing for broader access to psychedelic-assisted therapy as a potential treatment for various mental health conditions.
Critics of the FDA’s decision believe that the agency is too focused on the potential risks of psychedelic therapy and not enough on the potential benefits. They argue that MDMA therapy has been shown to be effective in clinical trials and could offer a new treatment option for those struggling with PTSD.
The rejection of MDMA therapy by the FDA has sparked a debate among mental health advocates, researchers, and policymakers about the future of psychedelic therapy in the United States. Advocates in Oregon are calling for more research and education on the potential benefits of psychedelic therapy, in the hopes of expanding access to these treatments for those in need.
Source
Photo credit news.google.com
